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ABSTRACT 
Alzheimer’s disease (AD) is an age-related neurodegenerative disease linked with increased production and/or 
deposition of amyloid-beta (Aβ) in the brain. The aim of the present study was to investigate the possible neuro-
protective effect of troxerutin on an animal model of Alzheimer's disease. Alzheimer model was induced by a 
single dose intracerebroventricular (ICV) injection of Aβ 1–42 (5 nmol/5 µl). Thereafter, troxerutin (300 mg/kg) 
was gavaged for 14 days. The hippocampal malondialdehyde (MDA) levels and enzymatic activities of superoxide 
dismutase (SOD), glutathione peroxidase (GPx), and acetylcholinesterase (AChE) were measured using enzyme-
linked immunosorbent assay (ELISA) method. In addition, the number of apoptotic cells in the dentate gyrus (DG) 
was assessed by TUNEL kit. The results showed that ICV microinjection of Aβ 1-42 increased MDA levels, re-
duced SOD and GPx, and increased AChE activities in the hippocampus. Chronic administration of troxerutin 
significantly attenuated MDA levels and AChE activity and increased SOD and GPx activities in the hippocampus. 
Moreover, the number of apoptotic cells was decreased by troxerutin treatment. Taken together, our study demon-
strated that troxerutin could increase the resistance of hippocampal neurons against apoptosis, at least in part, by 
diminishing the activity of AChE and oxidative stress. Therefore, troxerutin may have beneficial effects in the 
management of Alzheimer's disease. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a neuro-
degenerative disease characterized by pro-
gressive loss of memory and cognitive func-
tion (Butterfield and Boyd-Kimball, 2004). 
AD is the most common cause of dementia in 
the people over 65 years which imposes a sig-
nificant economic burden on families and so-
ciety, and remarkably decreases the quality of 
life (Takizawa et al., 2015). 
Two main neurological hallmarks in AD 
are extracellular senile plaques and intracellu-
lar neurofibrillary tangles in the brain regions 
critical for learning and memory, the hippo-
campus and other cortices, resulting in the 
loss of neurons and synapses (Blennow and 
Hampel, 2003; Giannakopoulos et al., 2003; 
Hardy and Selkoe, 2002). Although, the exact 
mechanism of AD remains unclear, it seems 
that alterations in the production and pro-
cessing of Aβ leads to accumulation of Aβ 
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plaques in the neuronal space of the brain 
(Bloom, 2014; Mayeux and Stern, 2012). 
Other proposed mechanisms associated with 
AD are mitochondrial dysfunction and oxida-
tive stress (Pohanka, 2014; Wang et al., 
2014), impairment of cholinergic transmis-
sion (Kumar and Singh, 2015), neuro-inflam-
mation (Morales et al., 2014), and glutamate 
neurotoxicity (Rudy et al., 2015). 
Oxidative stress is defined as an imbal-
ance between pro-oxidant stress and anti-oxi-
dant defense which may lead to tissue injury 
(Halliwell and Gutteridge, 1999). Previous 
studies support the vulnerability of the central 
nervous system (CNS) to oxidative stress pos-
sibly due to large rate of oxygen consumption, 
the richness of iron, high level of polyunsatu-
rated fatty acids, and low levels of antioxi-
dants (Butterfield et al., 2001; Paula et al., 
2005). Recent studies have highlighted the 
importance of oxidative processes in the path-
ogenesis of AD (Cioanca et al., 2015; E Abdel 
Moneim, 2015). Although the initiating 
events are still unknown, it has been proposed 
that oxidative damage is involved in the initi-
ation of AD and is the first apparent sign in 
progression of AD (Arimon et al., 2015; 
Wang et al., 2014). Antioxidant enzymes in-
cluding superoxide dismutase (SOD), thiore-
doxin, glutathione peroxidase (GPx), gluta-
thione reductase (GR), and catalase (CAT) 
form important protective mechanism against 
reactive oxygen species (ROS) (Birben et al., 
2012; Pohanka, 2014). Previous studies have 
shown that the activities of antioxidant en-
zymes are diminished, whereas the levels of 
oxidative stress markers are elevated in the 
brain of AD patients (Arimon et al., 2015; 
Krstic and Knuesel, 2013). 
Acetylcholine (ACh) and cholinergic sys-
tem are essential for regulation of learning 
and memory processes (Papandreou et al., 
2011). Previous studies showed that accumu-
lation of Aβ reduced ACh levels in the AD 
brain through increasing the expression of 
AChE (Perry et al., 1992). Moreover, AChE 
has the capability to augment Aβ deposition 
and fibril formation (Chacón et al., 2003). Un-
der normal conditions AChE is not an apop-
tosis initiator; however overexpression of 
AChE increases the sensitivity of cells to 
apoptosis (Zhang and Greenberg, 2012). Alt-
hough several agents such as cholinesterase 
inhibitors (Parsons et al., 2013), M1 musca-
rinic receptor agonists (Jiang et al., 2014), and 
some of phosphodiesterases (Fiorito et al., 
2013) are used to relieve symptoms of AD, 
most of these drugs are toxic and have numer-
ous side effects.  
Moreover, there is an inverse relationship 
between oxidative stress and Aβ levels. 
Persson et al. indicated that oxidative stress 
increased production and accumulation of 
Aβ, which in turn increased ROS production 
and mitochondrial dysfunction (Persson et al., 
2014). Several studies found that diminished 
number of neurons and synapses due to neu-
ronal apoptosis in the cerebral cortex and hip-
pocampus is the main reason of cognitive im-
pairment of AD (Morishima et al., 2001; 
Scheff et al., 2006). Since oxidative stress is a 
part of normal aging and starts very early in 
the disease progression, preventive therapies 
using antioxidants still hold great promise 
(Chakrabarti et al., 2014).  
Troxerutin, derivative of natural bioflavo-
noid rutin, is found in tea, coffee, cereals, and 
a variety of fruits and vegetables. Troxerutin 
possess biological properties such as antioxi-
dant (Panat et al., 2016) and anti-inflamma-
tory effects (Fan et al., 2009). Previously we 
demonstrated that oral administration of 
troxerutin improved synaptic failure (Babri et 
al., 2014) and learning and memory impair-
ments induced by ICV injection of Aβ (Babri 
et al., 2012).  
The aim of the present study was to inves-
tigate the effect of troxerutin on the hippo-
campal activity of AChE and oxidative status, 
and the number of neuronal apoptotic cells in 
the DG in Aβ 1-42-induced AD model in rats. 
 
MATERIALS AND METHODS 
Animals 
Sixty four adult male Wistar rats about 14 
weeks old, weighing 300 to 350 g were ob-
tained from Pasteur Institute of Iran and kept 
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at standard conditions four per cage, 22–
24 °C, 12 h light–dark cycle, and free access 
to food and water. All experiments were per-
formed in agreement with guidelines of the 
Tabriz University of Medical Sciences for 
care and use of laboratory animals. After one 
week of habituation animals were randomly 
allocated into the following groups (n=12 per 
each group): 
i) Sham operated 
ii) Reverse Aβ 42–1 (Bachem, Switzerland) 
iii) Aβ 1-42 (Bachem, Switzerland) 
iv) Aβ 1-42 + troxerutin (Merck, Germany). 
 
Surgical procedures 
In order to perform stereotaxic surgery, 
animals were deeply anesthetized by an intra-
peritoneal (i.p) injection of ketamine (80 mg/ 
kg) and xylazine (12 mg/kg) and placed on a 
stereotaxic instrument (Stoelting Co., Illinois, 
USA). The scalp was incised and a small hole 
was drilled at a proper location according to 
the Paxinos and Watson rat brain atlas (Pax-
inos, 2007). Aβ (5 nmol/5 µl), reverse Aβ 
(5 nmol/5 µl), or saline (5 µl) were injected 
into the right lateral ventricle (AP: −0.8, ML: 
1.6 and DV: 3.5 mm below dura) using a 
Hamilton micro syringe during 5 min. Needle 
was left in the place for 5 min before it was 
slowly withdrawn. Animals in the Aβ + 
troxerutin group received troxerutin (300 mg/ 
kg P.O for 14 days) one hour before injection 
of Aβ (Babri et al., 2012) and continued daily 
for 14 days. 
 
Assessment of hippocampal MDA levels 
and enzymatic activities of SOD, GPx and 
AChE 
At the end of experiments, rats were 
deeply anesthetized with 80 mg/kg sodium 
pentobarbital and sacrificed by decapitation, 
then hippocampal tissues were immediately 
removed. All samples were kept at -80 °C for 
later analysis. Samples were homogenized in 
1.15 % KCl solution and centrifuged at 
1000 rpm for 1 min at 4 °C for acquiring the 
supernatant. The supernatants were used for 
determination of MDA levels, and activities 
of SOD, GPx, and AChE. Hippocampal MDA 
level was measured using the thiobarbituric 
acid reactive substances (TBARS) method at 
535 nm with a UV spectrophotometer (Kaya 
et al., 2004). SOD, GPx, and AChE activities 
were measured using the commercial rat-spe-
cific ELISA kits (Randox Crumlin, UK) ac-
cording to the manufacturer’s protocols and 
expressed as U/mg protein and nmol/mg pro-
tein in tissue homogenate. 
 
Histological study 
Following deep anesthesia (80 mg/kg so-
dium pentobarbital) animals were perfused 
transcardially through the ascending aorta 
with 10–20 ml saline followed by 200 ml of 
4 % paraformaldehyde. The brain tissue was 
removed and post fixed in the same solution, 
then processed for histological assay. Paraffin 
embedded brain tissue was cut in 10 μm cor-
onal sections using a microtome. Brain sec-
tions were stained with TUNEL staining kit 
for determination of apoptotic cells in the 
dentate gyrus (DG) according to the manufac-
turer’s instructions. The numbers of apoptotic 
cells were counted by a blind person to the 
treatments using a light microscope (Nikon, 
Tokyo, Japan) at final magnification 400×. At 
least average TUNEL-positive cells of eight 
sequential brain sections from each animal 
were used for analysis.  
 
Statistical analysis 
Data were expressed as mean ± standard 
error of means (S.E.M.). Data were analyzed 
using SPSS (version 16) with One-way 
ANOVA followed by Tukey post-hoc test. 
Data of the histological changes were ana-
lyzed by the Kruskal-Wallis test followed by 
the post hoc Mann-Whitney test. Significance 
was assessed at the p<0.05 level. 
 
RESULTS 
Troxerutin attenuated hippocampal MDA 
levels  
To investigate the effect of chronic 
troxerutin treatment on oxidative stress, hip-
pocampal MDA level was measured (Figure 
1). Our results demonstrated that the level of 
MDA, an indicator of lipid peroxidation, in 
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the hippocampus was significantly (p<0.001) 
increased by Aβ 1-42 administration, while 
administration of reverse Aβ 42-1 had no sig-
nificant effect on MDA levels. On the other 
hand, treatment with troxerutin significantly 
(p<0.05) decreased MDA levels compared 
with Aβ treated animals.  
 
Figure 1: Effect of troxerutin on the hippocampal 
malondialdehyde (MDA) levels. Data are ex-
pressed as mean ± SEM for n=8 animals per 
group. *** p<0.001 vs. sham group and # p<0.05 
vs. Aβ group. 
 
 
Troxerutin enhanced antioxidant enzyme 
activities in the hippocampus 
The results revealed that Aβ 1-42 admin-
istration significantly decreased the activities 
of SOD (p<0.01) and GPx (p<0.001), indica-
tors of antioxidant defense, in the hippocam-
pus (Figure 2A and 2B, respectively). How-
ever, reverse Aβ 42-1 had no significant ef-
fects on the hippocampal SOD and GPx activ-
ities. Conversely, SOD (p<0.05) and GPx 
(p<0.01) activities were significantly in-
creased in the chronic troxerutin treated group 
as compared to the Aβ-received group.  
 
Troxerutin reduced the activity of AChE in 
the hippocampus 
In the current study, hippocampal activity 
of AChE, as a cholinergic marker, was also 
assessed. The one-way ANOVA analysis re-
vealed that Aβ 1-42 administration induced a 
significant (p<0.001) increase in the AChE 
activity (Figure 3). Nevertheless, treatment 
with troxerutin remarkably (p<0.01) attenu-
ated the hippocampal AChE levels. Reverse 
Aβ treatment did not significantly affect the 
hippocampal AChE levels. 
Figure 3: Effect of troxerutin treatment on the hip-
pocampal acetylcholinesterase (AChE) activity. 
Values are expressed as the mean ± SEM for n=8 
animals per group: ***p<0.001 vs. sham, ## p<0.01 
vs. Aβ group. 
 
 
 
 
 
 
 
Figure 2: Effect of troxerutin on (A) superoxide dismutase (SOD) and (B) glutathione reductase (GPx) 
activities in the hippocampus. Data are expressed as mean ± SEM for n=8 animals per group.**p<0.01, 
*** p<0.001 vs. the sham group and # p<0.05, ## p<0.01 vs. the Aβ group. 
EXCLI Journal 2017;16:1081-1089 – ISSN 1611-2156 
Received: June 01, 2017, accepted: July 17, 2017, published: August 09, 2017 
 
 
1085 
Troxerutin reduced the numbers of 
TUNEL-positive cells in the dentate gyrus 
Figure 4A shows the morphological fea-
tures of TUNEL-stained hippocampal sec-
tions. Histological study demonstrated that 
DG neurons were almost intact in the sham 
group; however, Aβ 1-42 administration in-
creased neuronal damage. Intriguingly, 
troxerutin treatment could decrease neuronal 
apoptosis induced by Aβ in rats. 
The results of Kruskal-Wallis analysis 
showed that the number of TUNEL-positive 
cells in the DG were significantly (p<0.001) 
increased in the Aβ-received group (Figure 
4B). In contrast, neurons were significantly 
(p<0.01) preserved in the troxerutin-treated 
group and sparse TUNEL-positive cells were 
found in the DG region of the hippocampus. 
No significant difference was observed be-
tween the sham and reverse Aβ-treated 
groups. 
DISCUSSION 
The present study showed that ICV injec-
tion of Aβ 1-42 increased hippocampal MDA 
and AChE levels and attenuated antioxidant 
enzymes activities (SOD and GPx). On the 
other hand, chronic troxerutin treatment for 
14 days significantly reduced MDA levels 
and AChE activity, and improved enzymatic 
antioxidant defense in the hippocampus. 
Moreover, troxerutin showed a neuroprotec-
tive effect and reduced the number of 
TUNEL-positive cells in the DG. 
Emerging evidence suggests that oxida-
tive damage plays a causal role in the patho-
genesis of AD (E Abdel Moneim, 2015). Prin-
cipal manifestation of oxidative stress in the 
CNS is lipid peroxidation occurring in the 
early phase of AD (Mattson, 2004; Qin et al., 
2009). Lipid peroxidation, in part, accounts  
 
 
 
 
Figure 4: Troxerutin prevents Aβ (1-42)-induced apoptosis in the dentate gyrus (DG). (A) TUNEL stain-
ing was used to identify apoptotic nuclei in response to Aβ administration (×400) [A: sham; B: Reverse 
Aβ; C: Aβ (1-42); D: Aβ + troxerutin]. Central injection of Aβ induced neuronal apoptosis (black arrows) 
in the DG (B) TUNEL-positive cell counts. Following β-amyloid injection, an increased number of apop-
totic cells were found in the dentate gyrus. Values are expressed as the mean ± SEM (n=4): ***p<0.001 
vs. sham group, ## p<0.01 vs. Aβ group. 
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for apoptosis and neurodegeneration in the 
AD brain. It has also been revealed that Aβ 1–
42 can lead to lipid peroxidation and neuronal 
apoptosis (Butterfield et al., 2001; Ivins et al., 
1999). 
In view of the fact that oxidative stress 
and impaired cholinergic system play a path-
ogenic role in AD, we investigated the effects 
of troxerutin on oxidative status in the hippo-
campus. Central injection of Aβ 1-42 pro-
vokes several impairments including oxida-
tive stress (Bagheri et al., 2011), cholinergic 
dysfunction (Olariu et al., 2001), and neu-
ronal apoptosis (Ivins et al., 1999; Ruan et al., 
2010) possibly through induction of protein 
oxidation and lipid peroxidation. In line with 
other studies, our results demonstrated that 
Aβ 1-42 increased oxidative stress in the hip-
pocampus which was confirmed by dimin-
ished enzymatic antioxidant defense and in-
creased MDA levels, end product of lipid pe-
roxidation (Butterfield and Boyd-Kimball, 
2004; Cioanca et al., 2013, 2015; Turunc Bay-
rakdar et al., 2014). Nevertheless, we found 
that administration of troxerutin (300 mg/kg) 
could significantly reverse MDA levels and 
enhance enzymatic antioxidant defense 
against Aβ 1-42 in the hippocampus. 
Acetylcholine, which involves in learning 
and memory processes, is degraded by AChE 
(Papandreou et al., 2011). In the AD brain, 
cholinergic activity decreases possibly due to 
increased activity of AChE around β-amyloid 
plaques (Moran et al., 1993). It is well known 
that increased AChE activity within and 
around amyloid plaques increases cytotoxi-
city by promoting the aggregation of amyloid 
beta-peptides into fibrils which is more toxic 
than Aβ fibrils (Chacón et al., 2003; Inestrosa 
et al., 2008; Reyes et al., 2004). Previous 
studies have also revealed that hyperactivity 
of AChE leads to memory deficit, and AChE 
inhibitors are effectively used for relieving 
symptoms of AD in rodents (Ballard et al., 
2005; Giacobini, 2004). In the present study, 
Aβ noticeably increased the hippocampal 
AChE activity, which was in accordance with 
previous study (Xu et al., 2017). Neverthe-
less, chronic troxerutin administration effec-
tively decreased AChE activity in the hippo-
campus induced by Aβ. Similarly, previous 
study has shown that troxerutin inhibits activ-
ity of AChE in the basal forebrain, hippocam-
pus, and frontal cortex of D-galactose-treated 
mice (Lu et al., 2010). Furthermore, it has 
been shown that oxidative stress is related to 
the brain AChE activity (Inestrosa et al., 
2008). Therefore, the reduction of the hippo-
campal AChE activity suggests that troxerutin 
is capable of improving memory impairment 
and oxidative stress induced by Aβ 1-42.  
The present study demonstrated that Aβ 1-
42 administration increased the number of 
TUNEL-positive cells in the DG. In support 
of our study, extensive evidence shows that 
accumulation of Aβ triggers neuronal apopto-
sis in the hippocampus, especially in the DG, 
which results in neuronal loss (Kadowaki et 
al., 2005; Obulesu and Lakshmi, 2014; 
Shimohama, 2000; Stadelmann et al., 1999; 
Yu et al., 2006). On the other hand, several 
studies indicated a protective role for troxeru-
tin in different tissues through inhibition of 
the oxidative stress markers (Elangovan and 
Pari, 2013; Fan et al., 2009; Lu et al., 2010; 
Zhang et al., 2009). Our results further 
showed that troxerutin reduced the TUNEL-
positive cell counts in the DG indicating a 
marked inhibitory effect on cell apoptosis. 
Similarly, Lu et al. showed that troxerutin in-
hibited endoplasmic reticulum stress-induced 
apoptosis in the hippocampus of mice (Lu et 
al., 2011). Therefore, troxerutin might reverse 
Aβ-induced neuronal loss through decreasing 
lipid peroxidation end product (MDA), inhib-
iting AChE activity, and enhancing the enzy-
matic antioxidant defense in the hippocam-
pus.  
Overall the findings of the present study 
revealed that troxerutin attenuates Aβ 1-42-
induced deleterious effects in the hippocam-
pus of rats. This is the first study showing the 
neuroprotective potential of troxerutin against 
Aβ 1-42-induced Alzheimer's disease possi-
bly through its anti-apoptotic, antioxidant, 
and AChE inhibitory effects in the hippocam-
pus.  
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